This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Date and time:

13.05.24 at 15:00-15:45 WEST



Opening and welcome

Unfolding the ATTR patient journey

Panel discussion and Q&A


Mathew Maurer

Columbia University Irving Medical Center, New York, USA

Dr Mathew Maurer is a General Internist and Geriatric Cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, New York, NY, USA and Vagelos College of Physicians and Surgeons, New York, NY, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). He is also a member of the Advanced Cardiac Care Center at New York Presbyterian Hospital – Columbia Campus, New York, NY.


Dr Maurer has published over 400 articles, including peer-reviewed manuscripts, reviews and book chapters. He was chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organisation dedicated to advancing the care of older adults with cardiovascular disease. He was the co-chair of the steering committee of the ATTR-ACT trial, showing tafamidis was an safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately affects older adults.    

Read full bio